Joel Greenblatt

Joel Greenblatt

Last Update: 11-15-2016

Number of Stocks: 913
Number of New Stocks: 219

Total Value: $7,679 Mil
Q/Q Turnover: 29%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Joel Greenblatt Watch

  • Altria Buys Sherman Group Holdings

    Altria Group Inc. (NYSE:MO) announced through the Business Wire the acquisition of the privately held Sherman Group Holdings and its subsidiary companies. The conditions of the deal are undisclosed.

    The company markets super-premium cigarettes and premium cigars under the Nat Sherman brand.


  • Undervalued Stocks Trading Below Peter Lynch Value

    According to GuruFocus' All-in-One Screener, several gurus are focusing on stocks whose Peter Lynch fair values are far above the current prices. The following stocks are trading with wide margins of safety and at least five gurus are shareholders.

    Wyndham Worldwide Corp. (WYN) is trading at about $77 per share. The Peter Lynch value gives the stock a fair price of $90.2 so the stock is undervalued with a margin of safety of 14%.


  • Eldorado Gold Reports Preliminary Operating Results for 2016

    Eldorado Gold Corp. (NYSE:EGO) announced its preliminary operational results for 2016 and its guidance for 2017 last Friday.

    For the last quarter of 2016, the Canadian gold miner produced 485,994 ounces of gold at an average cash operating cost of $578 per ounce.


  • Harmony Merger Inks Deal Greenblatt Favors

    Harmony Merger (NASDAQ:HRMN) came public as a blank check company – a company with nothing but cash and the intentions of making an acquisition.

    I’ve been a sucker for the Special Acquisition Corps (SPACs) since I saw Seth Klarman (Trades, Portfolio) holding a bunch of them a few years ago. Since the cash they have on their balance sheets usually supports their market valuation, there is quite a bit of downside protection.


  • Tweedy Browne Adds to MRC Global

    Investment firm Tweedy Browne (Trades, Portfolio) Co. increased its position in MRC Global Inc. (NYSE:MRC) by 7.6% on Dec. 31.

    Tweedy Browne was established in 1920 by Forrest Birchard Tweedy. Its current managing directors are William H. Browne, John D. Spears, Thomas H. Shrager and Robert Q. Wyckoff Jr. The firm’s investment approach is derived from the work of Benjamin Graham. It seeks to uncover a company’s intrinsic value by determining its acquisition value or by estimating the value of its assets and cash flow.


  • Valero Energy Upgraded by Bank of America Merrill Lynch

    Valero Energy Corp. (NYSE:VLO) got two opposite ratings Jan. 5.

    Bank of America Merrill Lynch upgraded Valero Energy from Neutral to Buy while Deutsche Bank downgraded the energy stock from Buy to Hold.


  • British American Tobacco Deal With Reynolds American Hits Road Bump

    A deal for British American Tobacco (BTI) to buy the rest of Reynolds American (NYSE:RAI) for $47 billion in cash and stock, has run into an unexpected problem, as reported by the website

    It is not exactly clear which problem is complicating the deal. Owen Bennett, analyst at Jefferies & Co., said that the problem "is likely to do with how BAT is choosing to sweeten the deal" and he suspects that the "deal is being driven by access to Reynolds heat not burn technology," as reported by the website


  • Lannet's Lopinavir, Ritonavir Approved to Treat HIV in US

    Lannet Co. Inc. (NYSE:LCI) announced through the PRNewswire Tuesday that its “Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg per mL” has been approved by the U.S. Food and Drug Administration (FDA) to be produced and sold in the U.S. as a generic drug.

    Lannett’s protease inhibitors, a class of antiretroviral drugs for the treatment of HIV positive patients and patients with AIDS, are equivalent to AbbVie’s (NYSE:ABBV) Kaletra oral solution.


  • 20 Questions With Value Investor Victor Huynh

    1. How and why did you get started in investing? What is your background?

    I started having exposure to investing in my first year of business school. Like many, I never pictured entering the investing environment. In fact, I did three years as a nursing student before making the switch to economics. From there, I started reading as much as I could, from every style of investing to studying the greats such as Buffett, Graham, Klarman, Cundill, Greenblatt, Pabrai, Lynch and many more. Oddly, my investment style started off with technical analysis, trading mainly options before progressing to deep value.


  • How to Invest in Gold in 2017 Part 5

    Gold for immdediate delivery witnessed a significant jump today. The precious metal increased by 1.08% on the London Bullion Market, up $12.2 per troy ounce to $1,146.80 per troy ounce from yesterday's closing price of $1,134.60.


  • 25 Questions With Tom Vilord of Vilord Wealth Advisors

    1. How and why did you get started investing? What is your background?

    I got started in the industry in 2000. I wanted to become a financial adviser because I wanted to learn how to research stocks like the guys on Wall Street. I wanted to learn what made Warren Buffett (Trades, Portfolio) so successful while most Americans failed to achieve success investing in the market. What did he know that the rest of us didn’t? After I passed my licensing exams, the company I was working for sent me to New York for three weeks of training. I thought this is when I was going to learn everything I needed to know to be a successful investor. Unfortunately, my first two weeks of training were nothing but sales training classes. The last week was training on all of the proprietary products. I was taught to be a salesperson. I learned absolutely nothing about how to invest money. And I was about to invest people's life savings. After a few years of not having a clue about what I was doing and having clients teach me stuff about the market, I started to self-teach myself. I bought every book I could read. I started taking personal one on one coaching courses, etc. I have been an adviser since 2000, but I have been an investor since 2005.


  • 25 Questions With Chris DeMuth Jr. of Rangeley Capital

    Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event-driven, value-oriented investment opportunities. Rangeley Capital and DeMuth's value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and DeMuth writes about them on StW.

    1. How and why did you get started investing? What is your background?


  • 18 Questions With John Huber of Saber Capital Management

    1. How and why did you get started investing? What is your background?

    I’ve always loved investing. My father was an engineer but was very active investing his savings in the stock market. By extension I became interested in stocks and investing relatively early on. But I came to the world of investment management unconventionally. I began my career in real estate, doing a variety of brokerage, investment and management activities in both residential and commercial real estate, and I established a few small partnerships with family members and friends to begin buying undervalued income-producing property. We bought residential properties as well as small multifamily properties.


  • Eldorado Gold Announces Approval of Revised Normal Course Issuer Bid by the TSX

    Eldorado Gold Corp. (NYSE:EGO) (TSX:ELD) announced on Monday that The Toronto Stock Exchange has approved its revised normal course issuer bid (NCIB), which allows the Canadian miner to buy back its own shares “through the facilities of the TSX and also through alternate Canadian trading systems.”

    The NCIB grants Eldorado permission to buy back a maximum volume of 2,081,168 of its ordinary shares, or about 0.30% of the total number of shares outstanding. The company had a total of 716,587,134 issued and outstanding shares as of Nov. 28.


  • AbbVie Files for Approval of Hepatitis C Treatment in the US

    AbbVie (NYSE:ABBV) announced today through PRNewswire that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its “investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).”

    The glecaprevir/pibrentasvir (G/P) regimen has been assessed on patients infected with chronic hepatitis C that have suffered kidney damage.


  • How to Invest in Gold in 2017

    With gold trending down, many investors interested in the industry are wondering which step to take. When the time comes, one of the ways to decide which gold mining stocks to invest in is analysing the characteristics of the gold industry and learning from the gurus’ moves.

    From Jan. 1 to Feb. 28, the price of gold on the London Bullion Market increased by 15.58%, as shown by the picture below that reports the following five sub-periods characterized by different trends in the gold price since the beginning of the year.


  • CEO of Intrexon Invests in Company

    Randal Kirk (Insider Trades), CEO and 10% owner of Intrexon Corp. (XON), purchased 34,606 shares on Dec. 13. The price per share was $28.90 for a total transaction of $1,000,113.

    Intrexon uses synthetic biology to create environmentally responsible products that meet the needs of the growing world population. The company has a market cap of $3.37 billion.


  • Watchlist Wednesday: Top 5 Magic Formula Stocks

    In this edition of Watchlist Wednesday, these are the top five stocks qualifying for the Magic Formula stock screen.

    This screen is influenced by the strategy discussed by Joel Greenblatt (Trades, Portfolio) in the book, "The Little Book That Still Beats the Market."


  • Joel Greenblatt More Than Doubles Home Depot Stake

    Guru Joel Greenblatt (Trades, Portfolio) more than doubled his stake in The Home Depot (NYSE:HD) during the third quarter, adding 345,905 shares of the company at an average price of $133.26 per share.

    The trade had a 0.58% impact on Greenblatt's portfolio. He owns 590,129 shares of the company.


  • Whole Foods Market Keeps Getting Cheaper

    Whole Foods Market's (NASDAQ:WFM) position has 200% growth potential from this price in the next decade, making it worth the risk. Let me start with the financials.

    Revenue is up 138% since 2007 totaling over $111 billion. That’s north of $35 million per store with gross margins at 34%.


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)